Impact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections.

IF 6.5 2区 医学 Q1 PHARMACOLOGY & PHARMACY
Mohammad Faizan Bhat, Sonja Srdanović, Lotta-Riina Sundberg, Helga Kristín Einarsdóttir, Varpu Marjomäki, Frank J Dekker
{"title":"Impact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections.","authors":"Mohammad Faizan Bhat, Sonja Srdanović, Lotta-Riina Sundberg, Helga Kristín Einarsdóttir, Varpu Marjomäki, Frank J Dekker","doi":"10.1016/j.drudis.2024.104193","DOIUrl":null,"url":null,"abstract":"<p><p>Innate immunity plays an important role in host defense against pathogenic infections. It involves macrophage polarization into either the pro-inflammatory M1 or the anti-inflammatory M2 phenotype, influencing immune stimulation or suppression, respectively. Epigenetic changes during immune reactions contribute to long-term innate immunity imprinting on macrophage polarization. It is becoming increasingly evident that epigenetic modulators, such as histone deacetylase (HDAC) inhibitors (HDACi), enable the enhancement of innate immunity by tailoring macrophage polarization in response to immune stressors. In this review, we summarize current literature on the impact of HDACi and other epigenetic modulators on the functioning of macrophages during diseases that have a strong immune component, such as infections. Depending on the disease context and the chosen therapeutic intervention, HDAC1, HDAC2, HDAC3, HDAC6, or HDAC8 are particularly important in influencing macrophage polarization towards either M1 or M2 phenotypes. We anticipate that therapeutic strategies based on HDAC epigenetic mechanisms will provide a unique approach to boost immunity against disease challenges, including resistant infections.</p>","PeriodicalId":301,"journal":{"name":"Drug Discovery Today","volume":null,"pages":null},"PeriodicalIF":6.5000,"publicationDate":"2024-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug Discovery Today","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.drudis.2024.104193","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Innate immunity plays an important role in host defense against pathogenic infections. It involves macrophage polarization into either the pro-inflammatory M1 or the anti-inflammatory M2 phenotype, influencing immune stimulation or suppression, respectively. Epigenetic changes during immune reactions contribute to long-term innate immunity imprinting on macrophage polarization. It is becoming increasingly evident that epigenetic modulators, such as histone deacetylase (HDAC) inhibitors (HDACi), enable the enhancement of innate immunity by tailoring macrophage polarization in response to immune stressors. In this review, we summarize current literature on the impact of HDACi and other epigenetic modulators on the functioning of macrophages during diseases that have a strong immune component, such as infections. Depending on the disease context and the chosen therapeutic intervention, HDAC1, HDAC2, HDAC3, HDAC6, or HDAC8 are particularly important in influencing macrophage polarization towards either M1 or M2 phenotypes. We anticipate that therapeutic strategies based on HDAC epigenetic mechanisms will provide a unique approach to boost immunity against disease challenges, including resistant infections.

HDAC 抑制剂对巨噬细胞极化的影响,以增强抗感染的先天免疫力。
先天免疫在宿主抵御病原体感染的过程中发挥着重要作用。它涉及巨噬细胞极化为促炎 M1 或抗炎 M2 表型,分别影响免疫刺激或抑制。免疫反应过程中的表观遗传变化有助于先天性免疫对巨噬细胞极化的长期印记。越来越明显的是,组蛋白去乙酰化酶(HDAC)抑制剂(HDACi)等表观遗传调节剂可通过定制巨噬细胞极化以应对免疫应激源,从而增强先天性免疫。在这篇综述中,我们总结了目前有关 HDACi 和其他表观遗传调节剂在感染等免疫成分较强的疾病中对巨噬细胞功能影响的文献。根据疾病的具体情况和所选择的治疗干预措施,HDAC1、HDAC2、HDAC3、HDAC6 或 HDAC8 在影响巨噬细胞向 M1 或 M2 表型极化方面尤为重要。我们预计,基于 HDAC 表观遗传机制的治疗策略将提供一种独特的方法来增强免疫力,以应对疾病挑战,包括耐药性感染。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Drug Discovery Today
Drug Discovery Today 医学-药学
CiteScore
14.80
自引率
2.70%
发文量
293
审稿时长
6 months
期刊介绍: Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed. Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信